<DOC>
	<DOC>NCT00567723</DOC>
	<brief_summary>Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.</brief_summary>
	<brief_title>Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Test Group Signed informed consent Patient must have ESRD and be receiving dialysis Prior treatment with Fosrenol for a minimum of 12 consecutive weeks Primary payer of healthcare must be Medicare (patient must supply Medicare Claim Number) Patient must be 18 years of age or older Test Group Patients that do not meet inclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>